How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Artificial intelligence (AI) may not be building better versions of itself yet, but Anthropic says the world is moving closer to that possibility than many people realize. In a new research paper ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

CNN's Wolf Blitzer leveled his inquisitive gaze at me and asked the biggest question in tech, “Is AI an existential threat to humanity?" I smiled confidently and assured Wolf, "No, I don't think it is ...

What was revolutionary about the clonal-selection theory as a solution to the specificity-of-antibody problem? N. Av Mitchison. Biology in the 1950s was coming to terms with 'DNA and all that'. We saw ...

A merge sort uses smaller, ordered lists which are easier to sort and merge than larger lists. It is usually more efficient and quicker than the bubble sort. It is more complex to code. It will still ...